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ess: pjones@sghms.ac.uSummary Evaluation of the effectiveness of treatment for chronic obstructive
pulmonary disease (COPD) requires the assessment of both clinical and physiological
measures. Parameters such as the forced expiratory volume in 1 s are well
established in providing an indication of the degree of airflow limitation. However,
additional measurements, such as dyspnoea, functional status and health status, are
required to provide a complete picture of COPD. Indeed, dyspnoea is the
predominant symptom of COPD experienced by the patient, which treatment is
designed to reduce. Methods of assessing dyspnoea have developed over the previous
five decades. The most widely used instruments for assessing the impact of dyspnoea
are the baseline dyspnoea index, the transition dyspnoea index and the Medical
Research Council Questionnaire.
A more comprehensive approach to the assessment of disability caused by
dyspnoea and fatigue is provided by assessments of functional status, such as the
pulmonary functional status and dyspnoea questionnaire. Respiratory-specific health
status questionnaires, such as the St. George’s Respiratory Questionnaire, attempt
to capture the wide range of effects of COPD into a single score that reflects the
overall impact of the disease.
Developing the means to measure the effects of COPD is important, both in terms
of understanding disease pathophysiology for research purposes, and in terms of
accurately assessing the effects of treatment on the patient. Future developments
will include computerising these methodologies to permit faster and more individual
patient-centred measurements.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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For some time, spirometric measurements such as
forced expiratory volume in 1 s (FEV1) have served
as core measures in chronic obstructive pulmonary
disease (COPD) research and in the assessment of
treatment response. However, FEV1 measures alone
are not sufficient to define treatment response, as
this marker does not fully reflect the pervasive
nature of, and the burden associated with, COPD.
Recent momentum in the field has increased the
number of treatment options available, which in
turn require adequate characterisation in terms of
their benefit to the patient.
A number of clinical and physiological outcomes,
such as dyspnoea, functional status and health
status, are recognised as being important for
characterising response to treatment. For instance,
dyspnoea is the primary reason for patients seeking
medical care. Measurements of dyspnoea provide
an insight into the practical effects of treatment on
everyday life, reflecting whether or not patients
perceive an improvement in this primary symptom
of COPD. Patients with COPD frequently decrease
their activity in order to avoid the unpleasant
sensation of breathlessness. Functional status
measurement reveals the number of activities that
a patient can perform—something not always
reflected in measurements of FEV1 or dyspnoea.
Health status provides an overall assessment of
patient quality of life (QoL), and is mainly
evaluated using questionnaires such as the St.
George’s Respiratory Questionnaire (SGRQ).1
This article examines the rationale for quantifying
breathlessness, functional status and health status,
and evaluates their application in COPD research,
alongside more established parameters such as FEV1
and exacerbation frequency. Challenges facing the
use of these measures and the direction of their
future development are also discussed.Methods for measuring dyspnoea in COPD
Why is it important to measure dyspnoea?
Dyspnoea is the primary symptom experienced by
patients with COPD, making the reduction of
breathlessness a central goal of treatment.2–4 It is
important to note that a patient’s perception of
dyspnoea does not necessarily increase with wor-
sening lung function and therefore cannot be
assumed to improve with FEV1.
5 Furthermore,
there may be improvements in dyspnoea, exercise
capacity and QoL with only minimal changes in
FEV1. Although measures such as FEV1 reflect directchanges in airflow limitation, it is important to
measure dyspnoea to reveal the practical effects of
treatment on a patient’s everyday life.6,7 In order
to address this requirement, questionnaires have
been developed, which grade a patient’s experi-
ence of his or her breathlessness.Unidimensional scales measuring dyspnoea
Because dyspnoea plays a central role in COPD,
methods have been developed to evaluate the
patient’s experience of breathlessness, either dur-
ing daily activities (questionnaires) or exercise
testing (the Borg scale). These measures have been
produced in order to grade the severity of dyspnoea
according to the degree of breathlessness asso-
ciated with particular tasks. Unidimensional scales
are useful for separating those who suffer from
dyspnoea from those who do not. For example, in
1959 Fletcher et al.8 developed a scale as part of a
survey of chronic bronchitis sufferers to establish
which type of activity (of five graded options)
subjects could complete before becoming hindered
by breathlessness. The Medical Research Council’s
(MRC) five-point scale ranges from patients only
being affected by dyspnoea during strenuous
exercise (grade 1), to severe dyspnoea preventing
patients from leaving the house or getting dressed
comfortably (grade 5).9 This scale has been used for
diagnostic evaluation and in clinical trials,2,10,11
and is still used to compare the categorisations of
dyspnoea with the staging of disease severity.12,13
Unidimensional scales tend to have the advan-
tage of being easy to administer and score. A
drawback, however, is the fact that patients may
modify their behaviour to avoid dyspnoea, for
example by using the lift instead of climbing the
stairs. Thus, unidimensional scales may be unable
to provide a completely accurate assessment of the
type of tasks which are likely to cause dyspnoea.
Furthermore, they do not take into account the
variation in effort which patients may exert in
completing certain activities. For example, climb-
ing the stairs at speed is likely to cause more acute
dyspnoea than slow climbing, which may cause
none at all, but both may be graded as a similar
activity. Lastly, scales which contain a relatively
small number of grades, such as the MRC scale, may
not be sensitive enough to reflect small changes
within the grades.14Multidimensional scales measuring dyspnoea
Multidimensional scales, such as the baseline
dyspnoea index (BDI) and the transition dyspnoea
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Table 1 Correlations (Pearson’s coefficients) be-
tween changes in patient-reported dyspnoea and
changes in lung function (N ¼ 27).
Dyspnoea measures Lung function parameters
DFEV1 DFVC DIC
DMRC 0.39 0.38 0.25
SAC TDI 0.63 0.58 0.57
D ¼ difference between baseline and follow-up values;
MRC ¼ Medical Research Council scale; SAC TDI ¼ self-
administered computerized transition dyspnoea index;
FEV1 ¼ forced expiratory volume in one second;
FVC ¼ forced vital capacity; IC ¼ inspiratory capacity.
Po0.05.
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comprehensive assessment of dyspnoea.14 These
tools also had to be precise enough to enable
comparison between patients in large clinical
trials. Currently, the most widely used of these
are the BDI and the TDI. Developed by Mahler and
colleagues in 1984,14 the BDI rates the severity of
dyspnoea at baseline and the TDI quantifies changes
from baseline. These indices cover information on
the individual components of dyspnoea: functional
impairment, magnitude of task needed to evoke
dyspnoea and magnitude of effort needed to evoke
dyspnoea. Since their introduction, the BDI/TDI
have been shown to be sufficiently responsive in
measuring improvements in patients treated with a
variety of therapeutic modalities.15–20
To estimate the minimal clinically important
difference of the TDI, Witek and Mahler21 analysed
the validity and pattern of response of the BDI/TDI
in a retrospective survey of 997 COPD patients who
received tiotropium, salmeterol or placebo in
addition to pre-existing treatment. Their analysis
showed a significant association between two
dyspnoea parameters (dyspnoea diary score and
the BDI/TDI). The BDI/TDI were also significantly
associated with spirometric (FEV1) and health
status outcomes. Moreover, the analysis demon-
strated that a 1-unit change in the TDI total score
was clinically relevant. These findings support a
previous retrospective analysis of 921 COPD pa-
tients, in which responders (TDIX1 unit) to treat-
ment also required significantly less supplemental
albuterol (Po0:05) and had significantly fewer
exacerbations (Po0:01) compared with non-re-
sponders (TDIp1 unit).22
These collective studies show that the BDI/TDI
are valid indices for use in clinical trials, and have
the ability to identify clinically important differ-
ences in dyspnoea.Interviewer-administered versus patient-
reported questionnaires
Criticisms of the BDI/TDI and similar tools include
their reliance upon open-ended questions and the
potential bias of the interviewer. The interview
process may also be time consuming. In order to
address these issues, both the BDI/TDI and the
chronic respiratory questionnaire (CRQ) can be self-
administered.23,24
In the self-administered computerised (SAC)
version of the TDI, patients are reminded of their
previous BDI grades, and then enter any changes in
dyspnoea on a continuous bidirectional visual
analogue scale (VAS).23 In one study performed toassess the validity and responsiveness of the
computerised versions, Mahler and colleagues
found a high correlation between the BDI/TDI
scores obtained from SAC and interviewer-adminis-
tered versions, when conducted in 25 patients (BDI,
r ¼ 0:83, Po0:0001; TDI, r ¼ 0:94, Po0:0001).23
Furthermore, scores from SAC and interview-
administered versions had similar correlations with
FEV1, forced vital capacity (FVC) and inspiratory
capacity (IC) at baseline and at follow-up. In a
preliminary study of 27 patients with COPD who
received either inhaled medication or pulmonary
rehabilitation, the SAC BDI/TDI, interview BDI/TDI
and the MRC questionnaires were administered in a
randomised order at baseline and follow-up.25
Correlation coefficients for SAC versus interview-
administered questionnaire were high (0.87 at
baseline and 0.68 at follow-up), and the correla-
tions for SAC TDI versus changes in lung function
parameters were higher than for MRC versus lung
function parameters (Table 1). Moreover, of the 16
patients who reported no change in dyspnoea on
the MRC scale, 10 patients reported a change in the
SAC TDIX1 unit (the clinically important differ-
ence). These data suggest firstly, that the SAC BDI/
TDI can be used in clinical trials and secondly, that
the SAC TDI is more sensitive to changes in
dyspnoea than the MRC questionnaire.
Discrete versus continuous methods of
measuring dyspnoea
Exercise testing is traditionally used to evaluate an
individual’s perception of dyspnoea, usually by
asking them at timed intervals during exercise to
choose a rating of their perceived exertion, on the
Borg scale or a ‘VAS’, which best describes their
breathlessness. Although discrete measurement of
dyspnoea has proved useful in research settings for
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Figure 1 Comparison between ‘discrete’ and ‘continu-
ous’ methods for evaluating dyspnoea during exercise (as
measured by work in watts), showing data from subjects
yielding (A) the ‘worst’ (r ¼ 0:94) and (B) the ‘best’
(r ¼ 0:98) mean correlation coefficient between results
from the two methods.27
P. Jones et al.S14the evaluation of effectiveness of therapeutic
interventions in COPD, its wider application may
have limitations. Firstly, a short test (for example
3–4min) will only provide a small number of
dyspnoea ratings, making it problematic to assign
a function to the data. Secondly, discrete ratings
may not accurately represent the continuous
change in dyspnoea experienced by the patient.26
Therefore, a continuous method of dyspnoea rating
has been developed whereby the patient moves a
computer mouse to indicate a change in dyspnoea
during a cycle test. Mahler et al. 27 have estab-
lished the validity and reliability of this method.
Their data indicated no significant difference
between discrete and continuous methods of
assessing dyspnoea during exercise (Fig. 1), even
when examining results from the subject yielding
the ‘worst’ mean correlation coefficient between
data obtained using the two methods. Further-
more, the continuous method proved more respon-sive to changes in dyspnoea induced by respiratory
load (i.e. transient changes) and yielded more
ratings of breathlessness compared with the dis-
crete method.27
Measuring dyspnoea—established principles
Some general conclusions can be drawn about the
requirements for instruments used to measure
dyspnoea. In particular, they should rely on
patient-reported outcomes, be multidimensional
where possible, adhere to standardised methodol-
ogy and ideally be computerised. These recom-
mendations should be upheld if the evaluation of
dyspnoea in COPD is to provide consistently reliable
data in future clinical trials.
Functional status in COPD
Definitions and influencing factors
Functional status refers to a patient’s ability to
participate in everyday activities. This is not only
influenced by lung function, indeed, comorbidities,
conditioning and motivation are all contributing
factors, as is the fact that some patients may
choose to perform activities despite the associated
dyspnoea. Measuring functional status should,
therefore, not rely on physiological changes alone,
and consequently is a complex parameter to assess.
Why is functional status so important?—A
case study
The need to evaluate functional status can be
illustrated by the following case study.28 A male
patient with COPD was monitored over 16 years,
during which time he underwent pulmonary reha-
bilitation and lung-volume–reduction surgery
(LVRS). During the first 13 years, the patient’s
dyspnoea and lung function ratings according to the
pulmonary functional status and dyspnoea ques-
tionnaire (PFSDQ) remained severe but stable
(Fig. 2). However, his functional status, defined as
the number of activities which he could no longer
perform from a specific set of 79 tasks, worsened
considerably. This worsening was not reflected in
his FEV1 or dyspnoea levels. Crucially, after the
patient underwent LVRS, his dyspnoea score fell
from 7 to 1 (on a scale where 10 is the most
severe), but his FEV1 improvement was o0.5 L.
However, after LVRS he resumed performing 33
activities which he had previously given up (Fig. 2).
These data demonstrate the complexity of func-
tional status and show how its evaluation adds to
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Figure 2 Case study data showing the functional status
of the patient (number of activities no longer performed)
and dyspnoea score (as measured by the pulmonary
functional status and dyspnoea questionnaire [PFSDQ]),
for the time before and after lung-volume–reduction
surgery (LVRS) and pulmonary rehabilitation. Measure-
ments of forced expiratory volume in 1 s (FEV1) are also
shown.28
Measuring the effects of COPD on the patient S15our understanding of the practical effects of COPD
on individual patients. Determining functional
status may also help assess which treatments are
most effective in specific patient populations,
where spirometric parameters provide insufficient
differentiation.Measurement of functional status
Methods of assessing functional status are still
evolving. Reasons for this state of affairs are three-
fold: daily activities are numerous, making it
difficult to include all those that are relevant;
different activities may be of different value to
specific patients; and the degree of dyspnoea
associated with activities may vary according to
the amount of effort exerted. Thus, measurement
tools need to comprise solutions for all of these
problems, if possible. Currently available options
include self reports, motion sensors and direct
observation through videotaping.Self reports
Self reports provide a patient’s assessment of their
activity, either by asking the patient about their
activity levels regardless of symptoms29 or by
asking patients to rate their symptoms associated
with specific activities.1,14,30 Although several of
these tools have demonstrated strong reliability,1,29
the data collected are qualitatively different
between tools and therefore cannot be compared
easily. Therefore, other methods need to be
examined.Activity monitors
Motion sensors ranging from pedometers to accel-
erometers allow the precise evaluation of activity
time and intensity. Although data collected this
way correlate well with physiological measures,
they do not appear to correlate with self reports
and may actually measure a different aspect of
patient activity. In support of this hypothesis, Belza
et al.31 showed that accelerometer data did not
correlate with most disease-specific self-reported
measures, although accelerometer data did corre-
late with FEV1 (Po0:01), 6-min walk distance
(Po0:01), and self efficacy (Po0:05). This con-
sideration, along with practical limitations, means
that the current role of motion sensors is mainly
limited to evaluating the frequency, intensity and
duration of walking activities during research.
However, in the future they may play a comple-
mentary role to self report measures in assessing
activity improvement after treatment.
Direct observation
Recently, methods of direct observation of activity
levels have been explored. Activity recorded on
video can be translated into units of motion or into
a three-dimensional report. One clear advantage of
direct observation is that, if used during rehabilita-
tion, it can help patients understand how to
perform activities more efficiently, for example
by modifying their breathing technique. Disadvan-
tages are mainly practical and include the en-
ormous amount of storage capacity required to
process the data, and potential issues of patient
privacy. A further element which is lacking from
direct observation is the capacity to monitor a
patient’s breathing pattern. However, the Life Shirt
(VivoMetricss; Ventura, CA, USA) may help to gain
a more complete picture of ventilatory mechanics
and dyspnoea.
Given the distinct but synergistic characteristics
of these three options for assessing functional
status, it is likely that the future gold standard
will not consist of a single measure alone but rather
be an optimal combination of different methods.
Establishing this combination strategy and improv-
ing the technology required for these systems are
therefore key goals in this area.COPD and health status
What role does health status play in COPD
research?
COPD has a substantial impact on patient overall
health and QoL. Health is an abstract concept, but
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Figure 3 Collated data showing the association between
P. Jones et al.S16it is possible to produce standardised health status
measures that have true interval-scaling properties
(i.e. the questionnaire behaves like a ruler). By
contrast, QoL is personal to each individual. Whilst
there is a relationship between reduced lung
function and impaired health,32 this is not suffi-
ciently strong for spirometric measures to provide a
reliable estimate of health-related quality of life
(HRQoL).33 For that reason, measurements of
health status must be made using specifically
designed questionnaires.33,34 A large body of
evidence now supports the use of these question-
naires to quantify the impact of COPD on the
patient’s daily life and well-being.32mortality and St. George’s Respiratory Questionnaire
(SGRQ) score.1,39–42HRQoL in COPD progression
Several generic questionnaires are currently in use,
for example the short form-36,35 EuroQol-5D35,36
and CRQ.30,35,36 Perhaps the most widely used
disease-specific health status questionnaire is the
SGRQ,1 which is a self-administered 50-item survey
encompassing three components: symptoms, activ-
ity and social or psychological impacts. Scored from
0 (best score) to 100 (worst score), a change of 4
units is deemed clinically significant. The scores
from this questionnaire are reproducible and
sensitive to change over extended time periods.
The ISOLDE trial (Inhaled Steroids in Obstructive
Lung Disease in Europe)37 showed that health status
declines at a measurable rate, which is influenced
by the rate of decline in FEV1 and the frequency of
exacerbations.38 The decline was seen in all three
components of the SGRQ showing that all aspects of
COPD worsen progressively. Long-term treatment
with fluticasone propionate reduced this rate of
deterioration in all three SGRQ components and the
overall score, showing for the first time that it is
possible to ameliorate the rate of progression of
loss of health in this disease.HRQoL, mortality and exacerbations
Several studies have tested whether or not there is
a relationship between health status (generic or
disease-specific instruments) and mortality.39–42
These studies provide strong evidence that survival
is reduced with higher (i.e. worse) SGRQ scores
(Fig. 3).1,39–42 However, it is unclear whether or not
all health status measures have the ability to
predict mortality.
The relationship between health status and
exacerbations is more precisely defined. Spencer
and Jones43 analysed data from the 26-week
gemifloxacin long-term outcomes in bronchitisexacerbations study, which included 438 patients
who had suffered from an acute exacerbation of
chronic bronchitis (AECB). Patients who suffered
repeated exacerbations during the study had a
significantly worse SGRQ score at baseline than
those who suffered no further AECB during the
trial. Faster recovery from the initial AECB was also
associated with a longer period to the next
exacerbation. Furthermore, Spencer et al.38 ana-
lysed data from the ISOLDE trial (N ¼ 613) and
showed that frequent exacerbations were indepen-
dently associated with a worse baseline SGRQ score
(Po0:0001) and a more rapid rate of deterioration
in health status (P ¼ 0:0003). Statistical modelling
suggested that the benefits from fluticasone pro-
pionate are largely the result of a reduction in
exacerbation frequency. In conclusion, exacerba-
tion frequency appears to have a marked effect on
health status, making it all the more important to
reduce exacerbations through treatment.Measuring health status: consequences and
inferences
Much has been learnt from the use of health status
measurements in clinical studies; and it is now
known that the SGRQ does have true interval
scaling properties. A difference of 4 units (the
threshold of clinical significance) at the mild end of
the disease spectrum has the same meaning as 4
units at the severe end. By contrast, the implica-
tions for a patient of a 4-unit change may differ
greatly between mild and severe disease. For
example, a 4-unit deterioration with an infection
may not even be enough to make a patient with
mild disease visit their doctor for an antibiotic, but
in the most severe patient a worsening of COPD
sufficient to produce a 4-unit change may trigger a
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about the relationship between baseline health
status, changes in health and their clinical con-
sequences.
Future developments in health status measure-
ment include refining and simplifying existing
instruments and the development of computerised
versions that can be used and scored in the clinic or
using the internet. These developments will still
not produce a major reduction in the time to
complete a comprehensive health status question-
naire (typically 8–15min currently), but the use of
sophisticated mathematical algorithms in computer
adaptive testing (CAT) could reduce this time to
1–2min. Even more attractive is the potential
power of CAT to make individual patient-tailored
HRQoL questionnaires a reality.Conclusions
Advances in measuring the effects of COPD may
prove to be equally as important as the develop-
ment of novel treatments for COPD. In this article,
we have examined how parameters of dyspnoea,
functional status and health status provide com-
plementary information to more established phy-
siological measures such as FEV1. With improved
treatment options in COPD, specific patient popu-
lations should be monitored accurately by applying
these methods in order to gain a complete picture
of their disease status. Only then will tailored
treatment programmes become a reality.References
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